bioihbjkbjnl/mcl2 huggingface dataset:
Influence of Episodic Memory on Healthy Eating
Condition: Eating Behavior
Study type: Interventional

Summary: 
      The present research project investigates if recall of recent eating episodes enhances
      consumption of fruits and vegetables
    

Detailed description: 
      Episodic memory is the capacity to remember past autobiographic events, including eating
      episodes. Recalling a previous meal decreases the amount eaten in a subsequent snack
      occasion.

      Recall of recent eating episodes could alert individuals about the relationship between their
      eating behaviour and wellbeing. This is supported by the observation in slimming trials that
      participants who keep a food diary lose more weight than those who do not record their
      intake.

      Lab experiments have focused on the effect of eating episodic memory on later intake of
      unhealthy food. However, less is known about the effect on intake of healthy food. Increasing
      consumption of food that contains nutritious elements like fruit could protect against
      chronic disease. If eating episodic memory would increase intake of healthy food, this would
      benefit individuals' health.

      The aim of the present between-subjects experiment is to test the influence of memory of
      recent eating episodes on fruit and vegetable consumption. The interest is to assess
      differences in amount of fruit/vegetables eaten in each of two conditions: (i) after a recall
      of eating episodes of the day before and (ii) after recall of activities of the day before
      excluding eating episodes. The hypothesis is that fruit/vegetable consumption after recalling
      eating episodes would be higher than after recalling non-eating related activities.

      The project will consist of four individual studies varying weight status of participants and
      test food: i) Female with healthy weight, and fruit as test food; ii) Female with healthy
      weight, and vegetable as test food; iii) Female with unhealthy weight, and fruit as test
      food; and iv) Female with unhealthy weight, and vegetable as test food.
    

Intervention name(s): Eating recall condition; Non-eating recall condition
Intervention type(s): Behavioral; Behavioral
Intervention description(s): Recall of eating episodes would increase subsequent intake of fruit or vegetable items; Recall of non-eating episodes would not influence subsequent intake of fruit or vegetable items
Other intervention name(s): Cognitive approaches for eating behaviour
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: The participants are allocated to one of the two conditions (experimental or control condition) of the study in a randomised sequence.
Masking: Single (Participant)
Primary purpose: Basic Science
Keywords: Episodic memory; Eating episodes; Fruit and vegetable intake
"Study of the Effects of Serum and Follicular Fluid Relaxin Levels on Ovarian Function in IVF Cycles"
Condition: Infertility; Reproductive Techniques, Assisted; Oocyte Maturation
MeSH terms: Infertility
Study type: Observational

Summary: 
      The study evaluated the effect of serum relaxin and follicular fluid levels on the number and
      quality of oocytes, fertilization, the number and quality of the embryos in IVF protocols.
    

Detailed description: 
      Relaxin is one of the promising indicators of oocyte quality and prognosis of the
      effectiveness of invitro fertilization protocols. The hormone plays an important role in the
      processes of folliculogenesis, growth and maturation of oocytes, development of embryos,
      implantation processes, pregnancy and childbirth. A pilot study was conducted on a group of
      patients undergoing infertility treatment using assisted reproductive technologies in the
      superovulation stimulation protocol using gonadotropin releasing hormone antagonists. Blood
      and follicular fluid samples were obtained on the day of transvaginal follicular puncture.
      The results allow us to consider the hormone relaxin as a promising predictor of the result
      of ovarian stimulation, the effectiveness of fertilization in IVF cycles.
    

Intervention name(s): Relaxin ELISA Kit
Intervention type(s): Diagnostic Test
Intervention description(s): Ovarian stimulation was carried out from day 3 of the menstrual cycle using a fixed protocol, with recombinant (Gonal-F, Pergoveris) or human menopausal gonadotropins (Meriofert), GnRH antagonist (ganirelix 0.25 mg). A recombinant human chorionic gonadotropin Ovitrel 250 μg or a GnRH agonist, Diferelin 0.2 mg, was used as an ovulation trigger.
Intervention MeSH terms: Methocarbamol
Observational model: Cohort
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        The study included patients undergoing treatment in the Department of Assisted Reproductive
        Technologies of The Research Institute of Obstetrics, Gynecology and Reproductology named
        after D.O. Ott, Saint Petersburg, Russia
      
Keywords: Infertility; Relaxin; Oocytes; Embryo quality; IVF
Virtual Reality Effects on Functional Capacity and Quality of Life of People With Parkinson's Disease
Condition: Parkinson Disease
MeSH terms: Parkinson Disease
Study type: Interventional

Summary: 
      Introduction: Parkinson's disease (PD) is a progressive neurodegenerative disorder of
      dopaminergic neurons that can cause some mobility limitations and it has association with
      quality of life (QOL) in patients with PD. Virtual reality (VR) has been used to treat of
      these patients Objective: Evaluate the functional capacity and QOL of individuals with PD
      using VR with X-Box Kinect®. Methods: Were selected 20 individuals classified as stages 1-3,
      aged 50-75 years. They were divided by lot into two groups (control and experimental) with
      ten patients in each. The group (CG) treated with exercises (conventional therapy) during
      five-week, with two sessions per week lasting 60 minutes, while the experimental group (EG)
      spent half the time with conventional physical therapy and other half of time in virtual
      rehabilitation (VR). Subjects were evaluated before and after treatment using the following
      scales: Unified Parkinson's Disease Rating Scale and Parkinson's Disease Questionnaire .
    


Intervention name(s): conventional physiotherapy; Virtual Reality with X- Box Kinect®
Intervention type(s): Other; Other
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Assess the Effect of Food on Avanafil Pharmacokinetic (PK), to Compare 2 Oral Formulations of Avanafil,and Investigate Dose Proportionality in Healthy Male Subjects
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      This study will assess the effect of food on the pharmacokinetics of avanafil (Formulation
      II); determine the relative bioavailability of two avanafil tablet formulations (Formulation
      I versus Formulation II) and will investigate the dose-proportionality of Formulation II
      avanafil tablet.
    

Detailed description: 
      In this Phase I, single-centre, open-label, randomized, four-period crossover study, each
      eligible subject will be randomized to receive the 4 treatments in a 4-way crossover fashion.
      The 4 treatments are as follows:

        -  Treatment A: 2x100 mg Formulation II avanafil tablet, fasted

        -  Treatment B: 2x100 mg Formulation II avanafil tablet, fed

        -  Treatment C: 2x100 mg Formulation I avanafil tablet, fasted

        -  Treatment D: 1x50 mg Formulation II avanafil tablet, fasted Subjects will report to the
           study site on the evening before each treatment and will remain at the site until the
           24-hour PK sample has been drawn. A single oral dose of avanafil tablets will be
           administered with 240 mL of water. A washout period of at least 5 days will occur
           between the treatments. Subjects in treatment groups A, C and D will fast at least 10
           hours prior to and for at least 4 hours following dosing. Subjects in treatment group B
           will eat a standardized high fat breakfast 30 prior to dosing. Standard meals will be
           provided uniformly to all subjects at approximately 4 and 9 hours after dosing, and an
           evening snack will be provided approximately 12 - 13 hours after dosing. Blood samples
           for the determination of plasma avanafil and its metabolite concentrations will be
           obtained from each subject at 0 (30 minutes pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,
           3, 4, 8, 12, 18 and 24 hours post-dose in each treatment period.

      Adverse events; laboratory evaluations; color vision testing (Treatment A only),
      electrocardiogram and physical examination, vital signs will be assessed at various times
      during the study.
    

Intervention name(s): Avanafil
Intervention type(s): Drug
Intervention description(s): Treatment A: 2x100 mg Formulation II avanafil tablet, fasted
Treatment B: 2x100 mg Formulation II avanafil tablet, fed
Treatment C: 2x100 mg Formulation I avanafil tablet, fasted
Treatment D: 1x50 mg Formulation II avanafil tablet, fasted
Other intervention name(s): TA-1790
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: avanafil; absoprion; bioavailability; food effect; dose-proportionality; TA-1790; Pharmacokinetics of avanafil
The DIET Trial - Dietetic Intervention in Psoriatic Arthritis
Condition: Arthritis, Psoriatic; Metabolic Syndrome
MeSH terms: Arthritis; Arthritis, Psoriatic; Metabolic Syndrome
Study type: Interventional

Summary: 
      Psoriasis (Ps) and psoriatic arthritis (PsA) are associated with increased risk of metabolic
      syndrome (MetS), body fatness and cardiovascular risk. Additionally, oxidative stress and
      inflammation are also contributing mechanisms on Ps and PsA. However, little is known about
      the influence of diet and micronutrients on the main outcomes of these diseases. The aim of
      the investigators is to evaluate the effectiveness of an intervention diet program on disease
      activity, metabolic profile and oxidative stress inpatients with Psoriasis and Psoriatic
      Arthritis.
    


Intervention name(s): Diet + supplementation; Diet + placebo; Placebo
Intervention type(s): Dietary Supplement; Dietary Supplement; Dietary Supplement
Intervention description(s): Supplementation of 1g of fish oil, 3 time a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.; Supplementation of 1g of soybean oil, 3 times a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.; Supplementation of 1g soybean oil, 3 times a day.
Allocation: Randomized
Intervention model: Factorial Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Prevention
Keywords: psoriatic arthritis; psoriasis; body composition; DXA measurements; spondyloarthritis; diet therapy; adipose tissue
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
Condition: HPV Infections
MeSH terms: Papillomavirus Infections
Study type: Interventional
Phase: Phase 2

Summary: 
      A study to evaluate the efficacy, immunogenicity, safety and tolerability of V501 in adult
      women
    


Intervention name(s): Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine; Comparator: Placebo
Intervention type(s): Biological; Biological
Intervention description(s): V501; Gardasil, 0.5 ml injection in 3 dosing regimen; Placebo 0.5 ml injection in 3 dosing regimen
Other intervention name(s): V501; Gardasil
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Prevention
Stamp-in-Safety Playground Safety Project
Condition: Injury Prevention
Study type: Interventional

Summary: 
      Playground injuries are common at childcare centers. Adequate adult supervision is an
      important component to reducing playground injuries in preschool children. The investigators
      studied the Stamp-in-Safety Program, an intervention to improve adult supervision and reduce
      children's risky playground behaviors.
    

Detailed description: 
      Using a non-equivalent control group design, we evaluated the Stamp-in-Safety program which
      increases the quality of adult supervision and rewards children for safe play. In an urban
      childcare center, 71 children, ages 3-5 years, and 15 teachers participated in the study. The
      primary outcome measures were teacher verbalizations (warnings, explanations, redirects),
      teacher location (core, outskirts, or fringe of playground), risk taking behaviors by
      children (using equipment appropriately), and number of injuries on the playground.
    

Intervention name(s): Stamp-in-Safety Curriculum; Stamp-in-Safety curriculum
Intervention type(s): Behavioral; Behavioral
Intervention description(s): 30 minute curriculum on playground safety; 30 minute lesson on playground supervision
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Prevention
Keywords: playground; injury prevention
Attention Bias Modification Versus Attention Control in Treatment of Social Anxiety
Condition: Social Anxiety Disorder (Social Phobia); Social Anxiety; Social Anxiety Disorder
MeSH terms: Anxiety Disorders; Phobia, Social
Study type: Interventional

Summary: 
      The purpose of this study is to compare the clinical efficacy of treatment using gaze
      contingent music reward therapy (GC-MRT) with attention control treatment based on a similar
      paradigm, for social anxiety disorder (SAD)
    

Detailed description: 
      This study examines the possibility that the effectiveness shown for GC-MRT in the treatment
      of SAD leans on attention control rather than bias modification. Therefore half of the
      participants will receive the classic GC-MRT course of treatment while the other half a
      version of the task with non-emotional stimuli (geometric shapes).
    

Intervention name(s): Attention Bias Modification; Attention Control
Intervention type(s): Behavioral; Behavioral
Intervention description(s): Feedback according to participants' viewing patterns, in order to modify their attention bias to threat; Feedback according to participants' viewing patterns, in order to strengthen their attention control
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: social anxiety; social phobia; attention bias modification; attention control
The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis
Condition: Liver Fibrosis; Liver Steatosis
MeSH terms: Liver Cirrhosis; Fatty Liver; Fibrosis
Study type: Interventional

Summary: 
      Evaluate the feasibility of the Liver Incyte system for liver elasticity measurement in
      healthy volunteers and patients with liver fibrosis. To evaluate the discriminatory ability
      of elasticity measurements generated by Liver Incyte for healthy volunteers versus patients
      with liver fibrosis in comparison to FibroScan measurements.
    

Detailed description: 
      This will be a prospective, open label, feasibility and validation study of the Liver Incyte
      system in patients with liver fibrosis (Cohort 1, n = 150) and healthy volunteers (Cohort 2,
      n = 50), for a total of 200 participants. The physician operator of the FibroScan, and the
      operator of the Shear wave vibro-elastography (S-WAVE) system, will not be blinded to the
      clinical diagnoses of the patients. All patients will undergo the testing with both FibroScan
      and Liver Incyte system at a single in-clinic visit.

      The liver stiffness of each participant will be assessed with the Liver Incyte Model B device
      and with FibroScan. The elasticity measurements from these two devices will be the primary
      outcome measure.

      The Liver Incyte system is designed as two models with differences in the ultrasound
      components only, description of the two models is below. Two sub-studies are included in this
      design as exploratory objectives. Model B will be utilized at all study sites and all study
      participants. Participants at the LAIR study site will also be evaluated using Model A, as
      well as Model B, for verification and to confirm consistency between designs. Participants
      will have the option to participate in the Magnetic Resonance Elastography (MRE) and Proton
      Density Fat Fraction (PDFF) portion of the study. MRE/PDFF is an optional procedure, which
      makes up a sub-study for this trial, this would require approximately 1 hour, and is open to
      any participant who is willing and has time for the extra study visit. The results of the
      MRE/PDFF sub-study will be included as an exploratory objective.
    

Intervention name(s): Liver Incyte
Intervention type(s): Device
Intervention description(s): Ultrasound elasticity imaging
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
Keywords: liver; ultrasound elastography
MK-0954E Study in Participants With Hypertension (MK-0954E-357)
Condition: Hypertension
MeSH terms: Hypertension; Essential Hypertension
Study type: Interventional
Phase: Phase 3

Summary: 
      This study is being done to evaluate the efficacy, safety, and tolerability of losartan
      potassium 50 mg (L50) + hydrochlorothiazide 12.5 mg (H12.5) + amlodipine besylate 5 mg (A5)
      (MK-0954E). The primary hypothesis is that L50/H12.5/A5 is more effective in lowering mean
      trough sitting diastolic blood pressure (SiDBP) after 8 weeks of treatment compared to L50+A5
      in Japanese participants with essential hypertension who are not adequately controlled
      following an 8-week treatment with filter period study drug (L50+A5).
    


Intervention name(s): losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E); Losartan potassium; Amlodipine besylate; Placebo to MK-0954E; Placebo to losartan potassium; Placebo to amlodipine besylate
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.; One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.; One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.; One tablet, containing placebo, orally, once daily, for 8 weeks.; One tablet, containing placebo, orally, once daily, for 8 weeks.; One capsule, containing placebo, orally, once daily, for 8 weeks.
Intervention MeSH terms: Losartan; Amlodipine; Hydrochlorothiazide
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Essential hypertension; Uncontrolled hypertension; Antihypertensive agents; Blood pressure
Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study
Condition: Hematologic Neoplasms
MeSH terms: Hematologic Neoplasms
Study type: Interventional
Phase: Phase 3

Summary: 
      It is hypothesized that a strategy using prophylactic oral Tranexamic Acid (TXA) with
      therapeutic platelet transfusions is safe and effective compared to prophylactic platelet
      transfusions in patients undergoing an autologous hematopoietic stem cell transplantation
      (who are at risk for bleeding).
    

Detailed description: 
      In Canada, over 1,500 autologous hematopoietic stem cell transplantations (ASCT) are
      performed annually for hematologic malignancies. It is currently standard practice to provide
      a prophylactic transfusion of platelets to prevent bleeding when the daily measured platelet
      count is less than 10 x 109/L. A patient may require up to six adult platelet doses during
      the post-transplant period. However, the true benefit of prophylactic platelet transfusions
      in the ASCT setting is unclear and has been called into question by several recent studies.

      Prophylactic platelet transfusions may not only be unnecessary, they may be detrimental to
      the patient. Among blood products, platelet transfusions are associated with the highest risk
      of both infectious and non-infectious complications: this would include bacterial infections
      and allergic /febrile reactions. Moreover, the potential overuse of platelet products places
      a significant burden on a scarce health care resource that is provided through volunteer
      donations.

      An alternative strategy to prevent bleeding and reduce the need for platelet transfusions
      involves administering Tranexamic Acid, an oral antifibrinolytic agent to stabilize blood
      clots and reduce bleeding. Tranexamic Acid is safe and effective in many clinical scenarios,
      and may be a reasonable alternative for prophylactic platelet transfusions. In the setting of
      ASCT, Tranexamic Acid may reduce bleeding and further enhance a strategy of therapeutic
      platelet transfusions where platelets are administered only in the event of active bleeding
      symptoms.

      The effect of prophylactic platelet transfusions and Tranexamic Acid on clinical, quality of
      life and economic outcomes in patients receiving ASCT is unknown. The primary aim of this
      research program is to perform a randomized controlled trial to determine whether a strategy
      of prophylactic Tranexamic Acid (with therapeutic platelet transfusions) is safe and
      effective compared to prophylactic platelet transfusions in patients undergoing ASCT. Before
      conducting a larger trial, the investigators first propose a pilot randomized controlled
      trial to determine the feasibility of such a study.
    

Intervention name(s): Tranexamic Acid
Intervention type(s): Drug
Intervention MeSH terms: Tranexamic Acid
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Other